A detailed history of Ikarian Capital, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 206,854 shares of AKRO stock, worth $11.2 Million. This represents 1.54% of its overall portfolio holdings.

Number of Shares
206,854
Previous 220,000 5.98%
Holding current value
$11.2 Million
Previous $11.7 Million 16.34%
% of portfolio
1.54%
Previous 3.58%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$42.18 - $54.33 $554,498 - $714,222
-13,146 Reduced 5.98%
206,854 $9.82 Million
Q2 2025

Aug 14, 2025

SELL
$34.04 - $56.28 $851,000 - $1.41 Million
-25,000 Reduced 10.2%
220,000 $11.7 Million
Q1 2025

May 15, 2025

BUY
$21.87 - $57.56 $5.36 Million - $14.1 Million
245,000 New
245,000 $9.92 Million
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $8.24 Million - $10.5 Million
200,000 New
200,000 $10.1 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $50.24 $1.86 Million - $2.51 Million
50,000 New
50,000 $1.91 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $2.52B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.